FeRiva 21/7® is a multivitamin and multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.1
This Voucher on Demand is applicable to prescription coverage for eligible commercially insured patients. Offer void where prohibited. No income restrictions apply. Other restrictions may apply. Offer effective 09/2024. Avion Pharmaceuticals reserves the right to rescind, revoke, or amend this offer without notice. For full terms and conditions, see below.
Savings will be automatically applied at the pharmacy when the prescription is filled. No physical coupon required.
Get FeRiva 21/7® consistently and conveniently with free home delivery. Glendale Pharmacy offers free standard shipping on all prescriptions to select states. Click here to confirm if Glendale delivers to your state.
Glendale Pharmacy also accepts health insurance in select states, which may reduce your out-of-pocket cost even further. Click here to confirm if Glendale accepts insurance in your state.
Terms and conditions may apply.
By using the Feriva® Savings Offer, you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions:
FeRiva 21/7® contains L-methylfolate calcium. The L-methylfolate ([6S]-N5-methyltetrahydrofolic acid calcium salt) in FeRiva 21/7® is less than 1.0% D-isomer.
Sumalate® is a registered trademark of Albion Laboratories, Inc., covered by one or more claims of U.S. Patent Nos. 6,716,814, 8,007,846, and 8,425,956.
Unless otherwise noted, all individuals depicted are models used for illustrative purposes only.
REFERENCES: 1. Feriva 21/7® Prescribing Information, Avion Pharmaceuticals, LLC, 2020 2. Kamdi SP, Palkar PJ. Efficacy and safety of ferrous asparto glycinate in the management of iron deficiency anaemia in pregnant women. J Obstet Gynaecol. 2014; Early Online: 1–5. doi:10.3109/01443615.2014.93008. Accessed December 29, 2014. 3. Bovell-Benjamin AC, Viteri FE, and Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr. 2000; 71:1563–1569. 4. Edited by Allen, L, de Benoist B, Dary O,Hurrel R. Guidelines on food fortification with micronutrients. World Health Organization and Food and Agricultural Organization of the United Nations. 2006; 97-100. 5. Fischer J.A., Cherian Arlin M, Bone Jeffrey M, Karakochuk Crystal D. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, VR, Vol. 00 (0): 1-17. Published by Oxford University Press on behalf of the International Life Sciences Institute. 6. Piskin, E., Cianciosi, D., Gulec, S., Tomas, M., & Capanoglu, E. (2022). Iron Absorption: Factors, Limitations, and Improvement Methods. ACS omega, 7(24), 20441–20456. https://doi.org/10.1021/acsomega.2c01833. 7. NIH. Dietary Supplement Fact Sheet: B12. Updated: March 26, 2024. Website. https://ods.od.nih.gov/factsheets/VitaminB12- HealthProfessional/. 8. Pietrzik K, Bailey L, Shane B. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010;49(8):535-548. doi:10.2165/11532990-000000000-00000.
This content is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pediatrician, or other qualified health provider with any questions you may have regarding diet and exercise during and after pregnancy, or other medical condition. For more information, please see our Terms of Use.
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.
DESCRIPTION: FeRiva 21/7® tablets for oral administration is a 28-day iron supplement regimen that consists of 21 red, oval-shaped iron tablets and 7 purple, oval-shaped inert tablets. Each red, oval-shaped iron tablet is debossed with “21” and “7” separated by a line in the middle on the top-side of the tablet and blank on the other side. Each purple, oval shaped inert tablet is blank on both sides of the tablet.
OTHER INGREDIENTS (RED IRON TABLETS): Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: FD&C Red #40, HPMC, Titanium Dioxide and Triacetin.
OTHER INGREDIENTS (PURPLE INERT TABLETS): Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: FD&C Blue #1, FD&C Red #3, HPMC, Titanium Dioxide and Triacetin.
INDICATIONS: FeRiva 21/7® is a multivitamin/multiminer- al dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.
CONTRAINDICATIONS: FeRiva 21/7® is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindicated to iron therapy.
PRECAUTIONS: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. While prescribing this nutritional supplement for pregnant women, nursing mothers or for women prior to conception, their medical condition and other drugs, herbs and/or supplements consumption should be considered.
ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
DOSAGE AND ADMINISTRATION: Usual dosage is one tablet daily with or without food or as prescribed by your healthcare provider. The FeRiva 21/7® Tablets blister pack supplies a 28-day course of iron therapy that consists of 21 red iron tablets and 7 purple inert tablets. Take 1 red iron tablet daily for 21 days, followed by 1 purple inert tablet daily for 7 days. After 28 tablets have been taken a new course may be started if prescribed.
HOW SUPPLIED: FeRiva 21/7® tablets blister pack (75854-318-28) contains 21 red iron tablets and 7 purple inert tablets. The listed product number is not a National Drug Code. Instead Avion Pharmaceuticals has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems.
Keep out of reach of children. Store at 20°C - 25°C (68°F - 77°F); excursions permitted to 15°C - 30°C (59°F - 86°F). [See USP Controlled Room Temperature.]
You may report side effects to Avion Pharmaceuticals, LLC at 1-888-612-8466 or to the FDA at 1-800-FDA-1088.
Please click here for full Prescribing Information, including Boxed Warning.
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.
DESCRIPTION: FeRiva 21/7® tablets for oral administration is a 28-day iron supplement regimen that consists of 21 red, oval-shaped iron tablets and 7 purple, oval-shaped inert tablets. Each red, oval-shaped iron tablet is debossed with “21” and “7” separated by a line in the middle on the top-side of the tablet and blank on the other side. Each purple, oval shaped inert tablet is blank on both sides of the tablet.
OTHER INGREDIENTS (RED IRON TABLETS): Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: FD&C Red #40, HPMC, Titanium Dioxide and Triacetin.
OTHER INGREDIENTS (PURPLE INERT TABLETS): Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: FD&C Blue #1, FD&C Red #3, HPMC, Titanium Dioxide and Triacetin.
INDICATIONS: FeRiva 21/7® is a multivitamin/multiminer- al dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.
CONTRAINDICATIONS: FeRiva 21/7® is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindicated to iron therapy.
PRECAUTIONS: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. While prescribing this nutritional supplement for pregnant women, nursing mothers or for women prior to conception, their medical condition and other drugs, herbs and/or supplements consumption should be considered.
ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
DOSAGE AND ADMINISTRATION: Usual dosage is one tablet daily with or without food or as prescribed by your healthcare provider. The FeRiva 21/7® Tablets blister pack supplies a 28-day course of iron therapy that consists of 21 red iron tablets and 7 purple inert tablets. Take 1 red iron tablet daily for 21 days, followed by 1 purple inert tablet daily for 7 days. After 28 tablets have been taken a new course may be started if prescribed.
HOW SUPPLIED: FeRiva 21/7® tablets blister pack (75854-318-28) contains 21 red iron tablets and 7 purple inert tablets. The listed product number is not a National Drug Code. Instead Avion Pharmaceuticals has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems.
Keep out of reach of children. Store at 20°C - 25°C (68°F - 77°F); excursions permitted to 15°C - 30°C (59°F - 86°F). [See USP Controlled Room Temperature.]
*THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR PREVENT ANY DISEASE.
You may report side effects to Avion Pharmaceuticals, LLC at 1-888-612-8466 or to the FDA at 1-800-FDA-1088.
Please click here for full Prescribing Information, including Boxed Warning.
By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply.